

# About IAVI



Translating science  
into global health impact

IAVI is a global nonprofit biomedical research organization that develops vaccines and antibodies for HIV, tuberculosis, and emerging infectious diseases. Our mission is to translate scientific discoveries into affordable, globally accessible public health solutions.

## Key program areas

IAVI brings together in-house researchers on infectious diseases, public and private partners, and local communities to develop and deliver vaccines and antibodies that are affordable and globally accessible. Here are the global health challenges we work on, some of the reasons we work on them, and what we're doing to help solve them.

### HIV

In 2024, 1.3 million people acquired HIV, primarily in low- and middle-income countries (LMICs). Treatment is still out of reach for many.

- Advance the next generation of vaccines to prevent HIV acquisition by pairing sophisticated science with community-rooted research.
- Develop injectable antibodies that can prevent HIV acquisition in babies for as long as six months with one dose.
- Partner with African institutions to end HIV by building on decades of investment, capacity strengthening, and leadership development.

### Tuberculosis (TB)

About one quarter of the world's population is infected with the bacterium that causes TB; 10.7 million people are estimated to have developed TB disease in 2024, resulting in approximately 1.23 million deaths.

- Conduct clinical trials of promising TB vaccine candidates in, and in partnership with, high-burden communities.

### Emerging Infectious Diseases

We need rapid, scalable vaccine technologies for diseases that pose public health and bioterror threats.

- Apply our viral vector vaccine technology expertise to develop vaccines against Lassa, Marburg, and Sudan virus diseases.

## Novel technologies and platforms

IAVI seeks to maximize the impact of novel technologies throughout our research portfolio so that innovations reach people in LMICs.

- Leverage our scientific, clinical, and access functions to improve access to innovative health solutions across disease areas.

## Product Development Center

IAVI's PDC bridges the "valley of death" in biomedical innovation development to help advance promising candidates from laboratory to clinic.

- Support for 53 biologics candidates to date, out of which 25 advanced to clinical trials.

### IAVI fast facts

30 years of breakthrough  
vaccine and antibody research

~260 employees

Global hubs in six countries: India, Kenya,  
Netherlands, South Africa, U.K., U.S.

Labs in La Jolla, California;  
Jersey City, New Jersey;  
and Faridabad, India

2024 revenue: \$139.5M

Revenue breakdown:  
44.3% governments;  
53.3% foundations and individuals;  
2.3% other sources

501(c)(3) nonprofit organization

## Pipeline 2026–2028

IAVI, in collaboration with partners in the public, private, and philanthropic sectors, develops vaccines and antibodies to address urgent, unmet global health challenges. Below is the pipeline as of February 2026. Go to [iavi.org](https://iavi.org) for the most updated list of [IAVI-led candidates](#) and [IAVI-supported candidates](#).

### IAVI products in development

Candidate Name		2026				2027				2028			
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
HIV vaccine candidates	Germline targeting preclinical antigen research	Preclinical											
	rVSVΔG-Env-HIV	Preclinical											
	eOD-GT8 60mer mRNA + coreg28v2 60mer mRNA; N332 GT5 mRNA	Phase 1 (IAVI G004)											
Emerging infectious diseases candidates	rVSVΔG-LASV-GPC	Phase 2 (IAVI C105)											
	rVSVΔG-SEBOV-GP	Phase 1 (Tokemeza)											
	rVSVΔG-SUDV-GP	Precl. Phase 1 (IAVI C109)											
	rVSVΔG-MARV-GP	Phase 1 (IAVI C104)											
	rVSVΔG-CCHFV-GPC	Preclinical											
TB vaccine candidates	MTBVAC*	Phase 2b (IAVI C113 IMAGINE)											
	mRNA-encoded TB antigens	Preclinical											

\* Trial in adults and adolescents. Biofabri industrially developed and in-licensed MTBVAC and is leading clinical development of the candidate in infants (currently in a Phase 3 trial).

### IAVI-supported candidates

Candidate Name		2026				2027				2028			
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
HIV vaccine candidate	GRAd networked T-cell epitope*	Phase 1 (IAVI C113)											
HIV bnAbs candidates	ePGT121v1-LS	Phase 1 (HVTN 141 / PedMab - 1ex)											
TB vaccine candidate	MTBVAC**	Phase 2a (HVTN605)											

\* Trial in people living with HIV and people living without HIV in Zimbabwe and South Africa. ReiThera is the vaccine contract development and manufacturing organization. Ragon Institute developed the networked epitope vaccine insert. Mutula Trust is the clinical lead.

\*\* Trial in adults and adolescents living with and without HIV. Biofabri industrially developed and in-licensed MTBVAC and is leading clinical development of the candidate in infants (currently in a Phase 3 trial).

## IAVI gratefully acknowledges the generous support provided by the following major funders:



Biomedical Advanced Research and Development Authority (BARDA) | Foundation for the National Institutes of Health | National Institute of Allergy and Infectious Diseases | amfAR, The Foundation for AIDS Research | Broadway Cares/Equity Fights AIDS | The City of New York, Economic Development Corporation | Congressionally Directed Medical Research Program (DoD) | GSK | The Hearst Foundations | Keith Haring Foundation | Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the USA and Canada)

And many other generous individuals and partners around the world

As of January 2026